Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials.

Niederman MS, Lee PC, Barriere SL, Barnes CN, Castaneda-Ruiz B.

Infect Dis Ther. 2019 Sep;8(3):445-452. doi: 10.1007/s40121-019-0255-0. Epub 2019 Aug 1.

2.

Disrupted Fear and Sadness Recognition in Binge Drinking: A Combined Group and Individual Analysis.

Lannoy S, Benzerouk F, Maurage P, Barrière S, Billieux J, Naassila M, Kaladjian A, Gierski F.

Alcohol Clin Exp Res. 2019 Sep;43(9):1978-1985. doi: 10.1111/acer.14151. Epub 2019 Aug 8.

PMID:
31329296
3.

GECKO is a genetic algorithm to classify and explore high throughput sequencing data.

Thomas A, Barriere S, Broseus L, Brooke J, Lorenzi C, Villemin JP, Beurier G, Sabatier R, Reynes C, Mancheron A, Ritchie W.

Commun Biol. 2019 Jun 20;2:222. doi: 10.1038/s42003-019-0456-9. eCollection 2019.

4.

Metabolic syndrome among older adults with schizophrenia spectrum disorder: Prevalence and associated factors in a multicenter study.

Abou Kassm S, Hoertel N, Naja W, McMahon K, Barrière S, Blumenstock Y, Portefaix C, Raucher-Chéné D, Béra-Potelle C, Cuervo-Lombard C, Guerin-Langlois C, Lemogne C, Peyre H, Kaladjian A, Limosin F; CSA Study group.

Psychiatry Res. 2019 May;275:238-246. doi: 10.1016/j.psychres.2019.03.036. Epub 2019 Mar 22.

PMID:
30933701
5.

Subsyndromal and syndromal depressive symptoms among older adults with schizophrenia spectrum disorder: Prevalence and associated factors in a multicenter study.

Hoertel N, Jaffré C, Pascal de Raykeer R, McMahon K, Barrière S, Blumenstock Y, Portefaix C, Raucher-Chéné D, Béra-Potelle C, Cuervo-Lombard C, Chevance A, Guerin-Langlois C, Lemogne C, Airagnes G, Peyre H, Kaladjian A, Limosin F; CSA Study group.

J Affect Disord. 2019 May 15;251:60-70. doi: 10.1016/j.jad.2019.03.007. Epub 2019 Mar 6.

PMID:
30904777
6.

Assessment of telavancin minimal inhibitory concentrations by revised broth microdilution method in phase 3 complicated skin and skin-structure infection clinical trial isolates.

Smart JI, Corey GR, Stryjewski ME, Wang W, Barriere SL.

Diagn Microbiol Infect Dis. 2017 Mar;87(3):268-271. doi: 10.1016/j.diagmicrobio.2016.12.009. Epub 2016 Dec 14.

7.

Efficacy of nonselective optogenetic control of the medial septum over hippocampal oscillations: the influence of speed and implications for cognitive enhancement.

Blumberg BJ, Flynn SP, Barriere SJ, Mouchati PR, Scott RC, Holmes GL, Barry JM.

Physiol Rep. 2016 Dec;4(23). pii: e13048.

8.

Self-defining memories in recently detoxified alcohol-dependent patients.

Cuervo-Lombard C, Raucher-Chéné D, Barrière S, Van der Linden M, Kaladjian A.

Psychiatry Res. 2016 Dec 30;246:533-538. doi: 10.1016/j.psychres.2016.09.040. Epub 2016 Sep 26.

PMID:
27821365
9.
10.

Temporal Coordination of Hippocampal Neurons Reflects Cognitive Outcome Post-febrile Status Epilepticus.

Barry JM, Sakkaki S, Barriere SJ, Patterson KP, Lenck-Santini PP, Scott RC, Baram TZ, Holmes GL.

EBioMedicine. 2016 May;7:175-90. doi: 10.1016/j.ebiom.2016.03.039. Epub 2016 Apr 6.

11.

Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.

Lacy MK, Stryjewski ME, Wang W, Hardin TC, Nogid B, Luke DR, Shorr AF, Corey GR, Barriere SL.

Clin Infect Dis. 2015 Sep 15;61 Suppl 2:S87-93. doi: 10.1093/cid/civ536.

PMID:
26316562
12.

Correction: Status Epilepticus Induced Spontaneous Dentate Gyrus Spikes: In Vivo Current Source Density Analysis.

Flynn SP, Barriere S, Scott RC, Lenck-Santini PP, Holmes GL.

PLoS One. 2015 Aug 14;10(8):e0136125. doi: 10.1371/journal.pone.0136125. eCollection 2015. No abstract available.

13.

Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance.

Pushkin R, Barriere SL, Wang W, Corey GR, Stryjewski ME.

Antimicrob Agents Chemother. 2015 Oct;59(10):6170-4. doi: 10.1128/AAC.00471-15. Epub 2015 Jul 27.

14.

Status Epilepticus Induced Spontaneous Dentate Gyrus Spikes: In Vivo Current Source Density Analysis.

Flynn SP, Barriere S, Scott RC, Lenck-Santini PP, Holmes GL.

PLoS One. 2015 Jul 6;10(7):e0132630. doi: 10.1371/journal.pone.0132630. eCollection 2015. Erratum in: PLoS One. 2015;10(8):e0136125. Barrier, Sylvain [corrected to Barriere, Sylvain].

15.

Mental healthcare in older adults with schizophrenia: results from 118 French public psychiatric departments.

Raucher-Chéné D, Hoertel N, Béra-Potelle C, Terrien S, Barrière S, Da Rin D, Tran E, Cuervo-Lombard C, Portefaix C, Limosin F.

Int Psychogeriatr. 2015 Oct;27(10):1749-50. doi: 10.1017/S1041610215001064. Epub 2015 Jul 6. No abstract available.

PMID:
26144544
16.

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment.

Worboys PD, Wong SL, Barriere SL.

Eur J Clin Pharmacol. 2015 Jun;71(6):707-714. doi: 10.1007/s00228-015-1847-6. Epub 2015 May 5.

17.

Clinical, economic and societal impact of antibiotic resistance.

Barriere SL.

Expert Opin Pharmacother. 2015 Feb;16(2):151-3. doi: 10.1517/14656566.2015.983077. Epub 2014 Dec 6.

PMID:
25483564
18.

Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.

Corey GR, Rubinstein E, Stryjewski ME, Bassetti M, Barriere SL.

Clin Infect Dis. 2015 Mar 1;60(5):787-96. doi: 10.1093/cid/ciu971. Epub 2014 Dec 3. Review.

19.

Serum inhibitory and bactericidal activity of telavancin in non-infected subjects with severe renal impairment or end-stage renal disease.

Barriere SL, Farrell DJ, Rhomberg PR, Jones RN.

Diagn Microbiol Infect Dis. 2014 Dec;80(4):327-9. doi: 10.1016/j.diagmicrobio.2014.09.002. Epub 2014 Sep 6.

20.

Variability in telavancin cross-reactivity among vancomycin immunoassays.

McConeghy KW, Liao S, Clark D, Worboys P, Barriere SL, Rodvold KA.

Antimicrob Agents Chemother. 2014 Dec;58(12):7093-7. doi: 10.1128/AAC.03785-14. Epub 2014 Sep 15.

21.

A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.

Stryjewski ME, Lentnek A, O'Riordan W, Pullman J, Tambyah PA, Miró JM, Fowler VG Jr, Barriere SL, Kitt MM, Corey GR.

BMC Infect Dis. 2014 May 23;14:289. doi: 10.1186/1471-2334-14-289.

22.

Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia.

Rubinstein E, Stryjewski ME, Barriere SL.

Infect Drug Resist. 2014 May 20;7:129-35. doi: 10.2147/IDR.S25930. eCollection 2014. Review.

23.
24.
25.

Telavancin for hospital-acquired pneumonia: clinical response and 28-day survival.

Corey GR, Kollef MH, Shorr AF, Rubinstein E, Stryjewski ME, Hopkins A, Barriere SL.

Antimicrob Agents Chemother. 2014;58(4):2030-7. doi: 10.1128/AAC.02330-13. Epub 2014 Jan 13. Erratum in: Antimicrob Agents Chemother. 2014 Jun;58(6):3581.

26.

Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure.

Torres A, Rubinstein E, Corey GR, Stryjewski ME, Barriere SL.

J Antimicrob Chemother. 2014 Apr;69(4):1119-26. doi: 10.1093/jac/dkt490. Epub 2014 Jan 6.

27.

Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers.

Ero MP, Harvey NR, Harbert JL, Janc JW, Chin KH, Barriere SL.

J Thromb Thrombolysis. 2014;38(2):235-40. doi: 10.1007/s11239-013-1004-y.

PMID:
24132401
28.

Telavancin versus vancomycin for bacteraemic hospital-acquired pneumonia.

Stryjewski ME, Barriere SL, Rubinstein E, Genter FC, Lentnek AL, Magana-Aquino M, Luna CM, Niederman MS, Torres A, Corey GR.

Int J Antimicrob Agents. 2013 Oct;42(4):367-9. doi: 10.1016/j.ijantimicag.2013.06.003. Epub 2013 Jul 26. No abstract available.

PMID:
23891527
29.

In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia.

Krause KM, Blais J, Lewis SR, Lunde CS, Barriere SL, Friedland HD, Kitt MM, Benton BM.

Diagn Microbiol Infect Dis. 2012 Dec;74(4):429-31. doi: 10.1016/j.diagmicrobio.2012.08.010. Epub 2012 Oct 16.

PMID:
23083812
30.

TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections.

Stryjewski ME, Potgieter PD, Li YP, Barriere SL, Churukian A, Kingsley J, Corey GR; TD-1792 Investigators Group.

Antimicrob Agents Chemother. 2012 Nov;56(11):5476-83. doi: 10.1128/AAC.00712-12. Epub 2012 Aug 6.

31.

Efficacy of telavancin in patients with specific types of complicated skin and skin structure infections.

Stryjewski ME, Barriere SL, O'Riordan W, Dunbar LM, Hopkins A, Genter FC, Corey GR.

J Antimicrob Chemother. 2012 Jun;67(6):1496-502. doi: 10.1093/jac/dks081. Epub 2012 Mar 13.

PMID:
22416054
32.

Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function.

Lodise TP, Butterfield JM, Hegde SS, Samara E, Barriere SL.

Antimicrob Agents Chemother. 2012 Apr;56(4):2062-6. doi: 10.1128/AAC.00383-11. Epub 2012 Jan 17.

33.

Population pharmacokinetics of telavancin in healthy subjects and patients with infections.

Samara E, Shaw JP, Barriere SL, Wong SL, Worboys P.

Antimicrob Agents Chemother. 2012 Apr;56(4):2067-73. doi: 10.1128/AAC.05915-11. Epub 2012 Jan 17.

34.

Presence of genes encoding panton-valentine leukocidin is not the primary determinant of outcome in patients with hospital-acquired pneumonia due to Staphylococcus aureus.

Sharma-Kuinkel BK, Ahn SH, Rude TH, Zhang Y, Tong SY, Ruffin F, Genter FC, Braughton KR, Deleo FR, Barriere SL, Fowler VG Jr.

J Clin Microbiol. 2012 Mar;50(3):848-56. doi: 10.1128/JCM.06219-11. Epub 2012 Jan 11.

35.

Methicillin-susceptible Staphylococcus aureus endocarditis isolates are associated with clonal complex 30 genotype and a distinct repertoire of enterotoxins and adhesins.

Nienaber JJ, Sharma Kuinkel BK, Clarke-Pearson M, Lamlertthon S, Park L, Rude TH, Barriere S, Woods CW, Chu VH, Marín M, Bukovski S, Garcia P, Corey GR, Korman T, Doco-Lecompte T, Murdoch DR, Reller LB, Fowler VG Jr; International Collaboration on Endocarditis-Microbiology Investigators.

J Infect Dis. 2011 Sep 1;204(5):704-13. doi: 10.1093/infdis/jir389. Erratum in: J Infect Dis. 2013 Feb 1;207(3):546.

36.

Effects of telavancin on coagulation test results.

Barriere SL, Goldberg MR, Janc JW, Higgins DL, Macy PA, Adcock DM.

Int J Clin Pract. 2011 Jul;65(7):784-9. doi: 10.1111/j.1742-1241.2011.02668.x. Epub 2011 May 13.

PMID:
21564449
37.

Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.

Rubinstein E, Lalani T, Corey GR, Kanafani ZA, Nannini EC, Rocha MG, Rahav G, Niederman MS, Kollef MH, Shorr AF, Lee PC, Lentnek AL, Luna CM, Fagon JY, Torres A, Kitt MM, Genter FC, Barriere SL, Friedland HD, Stryjewski ME; ATTAIN Study Group.

Clin Infect Dis. 2011 Jan 1;52(1):31-40. doi: 10.1093/cid/ciq031. Erratum in: Clin Infect Dis. 2019 Mar 5;68(6):1070.

38.

ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections.

Barriere SL.

Future Microbiol. 2010 Dec;5(12):1765-73. doi: 10.2217/fmb.10.138. Epub 2010 Nov 17.

PMID:
21080861
39.

In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies.

Krause KM, Barriere SL, Kitt MM, Benton BM.

Diagn Microbiol Infect Dis. 2010 Oct;68(2):181-5. doi: 10.1016/j.diagmicrobio.2010.05.008.

PMID:
20846593
40.

Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women.

Goldberg MR, Wong SL, Shaw JP, Kitt MM, Barriere SL.

Pharmacotherapy. 2010 Aug;30(8):806-11. doi: 10.1592/phco.30.8.806.

PMID:
20653356
41.

Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective.

Barriere SL.

Clin Infect Dis. 2010 Aug 1;51 Suppl 1:S4-9. doi: 10.1086/653033. Review. Erratum in: Clin Infect Dis. 2010 Nov 1;51(9):1114.

PMID:
20597670
42.

Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects.

Wong SL, Goldberg MR, Ballow CH, Kitt MM, Barriere SL.

Pharmacotherapy. 2010 Feb;30(2):136-43. doi: 10.1592/phco.30.2.136.

PMID:
20099988
43.

Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin.

Goldberg MR, Wong SL, Shaw JP, Kitt MM, Barriere SL.

Pharmacotherapy. 2010 Jan;30(1):35-42. doi: 10.1592/phco.30.1.35.

PMID:
20030471
44.

Telavancin and hydroxy propyl-beta-cyclodextrin clearance during continuous renal replacement therapy: an in vitro study.

Patel JH, Churchwell MD, Seroogy JD, Barriere SL, Grio M, Mueller B.

Int J Artif Organs. 2009 Oct;32(10):745-51.

PMID:
19943236
45.

Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial.

Bae IG, Tonthat GT, Stryjewski ME, Rude TH, Reilly LF, Barriere SL, Genter FC, Corey GR, Fowler VG Jr.

J Clin Microbiol. 2009 Dec;47(12):3952-7. doi: 10.1128/JCM.01643-09. Epub 2009 Oct 21.

46.

Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants.

Wong SL, Sörgel F, Kinzig M, Goldberg MR, Kitt MM, Barriere SL.

J Clin Pharmacol. 2009 Jul;49(7):816-23. doi: 10.1177/0091270009337133. Epub 2009 May 14.

PMID:
19443680
47.

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures.

Wilson SE, O'Riordan W, Hopkins A, Friedland HD, Barriere SL, Kitt MM; ATLAS Investigators.

Am J Surg. 2009 Jun;197(6):791-6. doi: 10.1016/j.amjsurg.2008.05.012. Epub 2008 Dec 18.

PMID:
19095213
48.

Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections.

Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JL.

Pharmacotherapy. 2008 Dec;28(12):1471-82. doi: 10.1592/phco.28.12.1471.

PMID:
19025428
49.

Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects.

Wong SL, Barriere SL, Kitt MM, Goldberg MR.

J Antimicrob Chemother. 2008 Oct;62(4):780-3. doi: 10.1093/jac/dkn273. Epub 2008 Jun 26.

PMID:
18586659
50.

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.

Stryjewski ME, Graham DR, Wilson SE, O'Riordan W, Young D, Lentnek A, Ross DP, Fowler VG, Hopkins A, Friedland HD, Barriere SL, Kitt MM, Corey GR; Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study.

Clin Infect Dis. 2008 Jun 1;46(11):1683-93. doi: 10.1086/587896.

PMID:
18444791

Supplemental Content

Loading ...
Support Center